Marwa Ahmed Mohamed, Zainab Ali-Eldin, Heba Aly, Dina Fathy, Yasser Hussein Mohamed, Mohamed Magdy Salama
{"title":"预后营养指数在预测接受索拉非尼和瑞非尼治疗的埃及晚期肝细胞癌患者生存中的价值","authors":"Marwa Ahmed Mohamed, Zainab Ali-Eldin, Heba Aly, Dina Fathy, Yasser Hussein Mohamed, Mohamed Magdy Salama","doi":"10.1186/s43094-025-00873-9","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>This investigation aims to assess the prognostic significance of the pre-therapeutic prognostic nutritional index (PNI) in individuals with hepatocellular carcinoma (HCC) undergoing treatment with either sorafenib or regorafenib.</p><h3>Methods</h3><p>A retrospective cohort study was conducted on 150 patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C HCC treated with sorafenib (n = 130) or regorafenib (n = 20) between September 2021 and January 2024. PNI was calculated as 10 × albumin (g/dL) + 0.005 × lymphocyte count (/mm<sup>3</sup>). Outcomes included overall survival (OS), progression-free survival (PFS), and radiological response (mRECIST).</p><h3>Results</h3><p>A PNI cutoff of 40.6 (sensitivity: 70%, specificity: 61%) stratified patients into high and low PNI groups. High PNI was significantly associated with longer OS in both sorafenib (6 vs. 3.3 months, <i>P</i> < 0.001) and regorafenib (8 vs. 3.7 months, <i>P</i> < 0.01) cohorts. Similarly, PFS was significantly prolonged in high PNI patients (sorafenib: 4.95 vs. 3 months; regorafenib: 7.7 vs. 3.1 months). Multivariate analysis confirmed high PNI and low albumin–bilirubin score (ALBI) score as independent predictors of OS and PFS.</p><h3>Conclusions</h3><p>Pretreatment PNI is a reliable, cost-effective predictor of OS and PFS in advanced HCC patients treated with sorafenib or regorafenib. Alongside Child–Pugh and ALBI scores, PNI may help guide personalized treatment strategies by identifying patients most likely to benefit.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00873-9","citationCount":"0","resultStr":"{\"title\":\"The value of prognostic nutritional index in predicting the survival of Egyptian patients with advanced hepatocellular carcinoma treated with sorafenib and regorafenib\",\"authors\":\"Marwa Ahmed Mohamed, Zainab Ali-Eldin, Heba Aly, Dina Fathy, Yasser Hussein Mohamed, Mohamed Magdy Salama\",\"doi\":\"10.1186/s43094-025-00873-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>This investigation aims to assess the prognostic significance of the pre-therapeutic prognostic nutritional index (PNI) in individuals with hepatocellular carcinoma (HCC) undergoing treatment with either sorafenib or regorafenib.</p><h3>Methods</h3><p>A retrospective cohort study was conducted on 150 patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C HCC treated with sorafenib (n = 130) or regorafenib (n = 20) between September 2021 and January 2024. PNI was calculated as 10 × albumin (g/dL) + 0.005 × lymphocyte count (/mm<sup>3</sup>). Outcomes included overall survival (OS), progression-free survival (PFS), and radiological response (mRECIST).</p><h3>Results</h3><p>A PNI cutoff of 40.6 (sensitivity: 70%, specificity: 61%) stratified patients into high and low PNI groups. High PNI was significantly associated with longer OS in both sorafenib (6 vs. 3.3 months, <i>P</i> < 0.001) and regorafenib (8 vs. 3.7 months, <i>P</i> < 0.01) cohorts. Similarly, PFS was significantly prolonged in high PNI patients (sorafenib: 4.95 vs. 3 months; regorafenib: 7.7 vs. 3.1 months). Multivariate analysis confirmed high PNI and low albumin–bilirubin score (ALBI) score as independent predictors of OS and PFS.</p><h3>Conclusions</h3><p>Pretreatment PNI is a reliable, cost-effective predictor of OS and PFS in advanced HCC patients treated with sorafenib or regorafenib. Alongside Child–Pugh and ALBI scores, PNI may help guide personalized treatment strategies by identifying patients most likely to benefit.</p></div>\",\"PeriodicalId\":577,\"journal\":{\"name\":\"Future Journal of Pharmaceutical Sciences\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00873-9\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1186/s43094-025-00873-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43094-025-00873-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
目的本研究旨在评估治疗前预后营养指数(PNI)在接受索拉非尼或瑞非尼治疗的肝细胞癌(HCC)患者中的预后意义。方法在2021年9月至2024年1月期间,对150例接受索拉非尼(n = 130)或瑞非尼(n = 20)治疗的巴塞罗那临床B/C期HCC患者进行回顾性队列研究。PNI计算为10 ×白蛋白(g/dL) + 0.005 ×淋巴细胞计数(/mm3)。结果包括总生存期(OS)、无进展生存期(PFS)和放射反应(mRECIST)。结果PNI临界值为40.6(敏感性为70%,特异性为61%),将患者分为高、低PNI组。在索拉非尼(6个月对3.3个月,P < 0.001)和瑞非尼(8个月对3.7个月,P < 0.01)队列中,高PNI与较长的生存期显著相关。同样,高PNI患者的PFS显著延长(索拉非尼:4.95 vs. 3个月;瑞非尼:7.7 vs. 3.1个月)。多因素分析证实高PNI和低ALBI评分是OS和PFS的独立预测因子。结论:在接受索拉非尼或瑞非尼治疗的晚期HCC患者中,治疗前PNI是一个可靠的、具有成本效益的OS和PFS预测指标。与Child-Pugh和ALBI评分一样,PNI可以通过识别最有可能受益的患者来帮助指导个性化的治疗策略。
The value of prognostic nutritional index in predicting the survival of Egyptian patients with advanced hepatocellular carcinoma treated with sorafenib and regorafenib
Objectives
This investigation aims to assess the prognostic significance of the pre-therapeutic prognostic nutritional index (PNI) in individuals with hepatocellular carcinoma (HCC) undergoing treatment with either sorafenib or regorafenib.
Methods
A retrospective cohort study was conducted on 150 patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C HCC treated with sorafenib (n = 130) or regorafenib (n = 20) between September 2021 and January 2024. PNI was calculated as 10 × albumin (g/dL) + 0.005 × lymphocyte count (/mm3). Outcomes included overall survival (OS), progression-free survival (PFS), and radiological response (mRECIST).
Results
A PNI cutoff of 40.6 (sensitivity: 70%, specificity: 61%) stratified patients into high and low PNI groups. High PNI was significantly associated with longer OS in both sorafenib (6 vs. 3.3 months, P < 0.001) and regorafenib (8 vs. 3.7 months, P < 0.01) cohorts. Similarly, PFS was significantly prolonged in high PNI patients (sorafenib: 4.95 vs. 3 months; regorafenib: 7.7 vs. 3.1 months). Multivariate analysis confirmed high PNI and low albumin–bilirubin score (ALBI) score as independent predictors of OS and PFS.
Conclusions
Pretreatment PNI is a reliable, cost-effective predictor of OS and PFS in advanced HCC patients treated with sorafenib or regorafenib. Alongside Child–Pugh and ALBI scores, PNI may help guide personalized treatment strategies by identifying patients most likely to benefit.
期刊介绍:
Future Journal of Pharmaceutical Sciences (FJPS) is the official journal of the Future University in Egypt. It is a peer-reviewed, open access journal which publishes original research articles, review articles and case studies on all aspects of pharmaceutical sciences and technologies, pharmacy practice and related clinical aspects, and pharmacy education. The journal publishes articles covering developments in drug absorption and metabolism, pharmacokinetics and dynamics, drug delivery systems, drug targeting and nano-technology. It also covers development of new systems, methods and techniques in pharmacy education and practice. The scope of the journal also extends to cover advancements in toxicology, cell and molecular biology, biomedical research, clinical and pharmaceutical microbiology, pharmaceutical biotechnology, medicinal chemistry, phytochemistry and nutraceuticals.